Tirzepatide TFA (LY3298176 TFA, GIP and GLP-1 receptor agonist)-Therapeutic peptides drug benchmark for in-vivo/in-vitro study

Cat No.: GMP-Bios-peptide-001

Product Name: Tirzepatide TFA

Structural formula:

Picture loading failed.

Tirzepatide TFA, the trifluoroacetic acid salt form of Tirzepatide. Tirzepatide, a new glucose-lowering therapy for diabetes, is called a “dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist”. Drug company Lilly released important results showing that this new therapy may be extremely effective for people with type 2 diabetes. Across three clinical trials, tirzepatide reduced A1C by an average of 2.5 percentage points and led to a weight loss of about 25 pounds.



Order information

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-peptide-001-5mg 5mg 780
GMP-Bios-peptide-001-25mg 25mg 1950
GMP-Bios-peptide-001-50mg 50mg 2925
GMP-Bios-peptide-001-100mg 100mg 3900
GMP-Bios-peptide-001-500mg 500mg 7800
GMP-Bios-peptide-001-xmg ≥500mg Inquiry
Shipping Cost: 760.00
Total:

For more than 500mg, click here for inquiry. >>


Description

Product NameTirzepatide TFA
Brand nameNA (also known as LY3298176 TFA) 
CAS No.2023788-19-2
FormulaC227H349F3N48O70
Biological ActivityTirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
PurityPurity: ≥98% (HPLC)
ApplicationTherapeutic peptides drug benchmark or raw material for peptide drugs or peptide conjugation drugs discovery and development.
Predicted Molecular Mass4927.47
FormulationPowder
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.